Roanna Ruiz
Stock Analyst at Leerink Partners
(0.80)
# 3,928
Out of 4,969 analysts
64
Total ratings
32.5%
Success rate
-15.97%
Average return
Main Sectors:
Stocks Rated by Roanna Ruiz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $7 → $9 | $7.84 | +14.80% | 6 | Aug 19, 2025 | |
| AKBA Akebia Therapeutics | Initiates: Outperform | $7 | $3.12 | +124.36% | 1 | Apr 28, 2025 | |
| CRMD CorMedix | Initiates: Outperform | $18 | $13.70 | +31.39% | 1 | Mar 7, 2025 | |
| LXRX Lexicon Pharmaceuticals | Downgrades: Market Perform | $1 | $1.09 | -8.26% | 1 | Mar 4, 2025 | |
| VIR Vir Biotechnology | Maintains: Outperform | $18 → $20 | $5.52 | +262.38% | 4 | Jan 13, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Outperform | $26 → $27 | $10.88 | +148.16% | 4 | Jan 13, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | $12 → $13 | $3.95 | +229.53% | 3 | Oct 25, 2024 | |
| ARDX Ardelyx | Initiates: Outperform | $14 | $6.52 | +114.89% | 1 | Apr 5, 2024 | |
| UTHR United Therapeutics | Initiates: Outperform | $330 | $391.24 | -15.65% | 1 | Feb 5, 2024 | |
| CYTK Cytokinetics | Initiates: Outperform | $58 | $49.99 | +16.02% | 1 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $25 | $71.30 | -64.94% | 1 | Apr 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | $49 | $8.84 | +454.30% | 10 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $13 | $5.51 | +135.93% | 7 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $6 | $3.46 | +73.66% | 6 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $24.89 | -23.66% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $120 | $55.15 | +117.59% | 3 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $75 → $50 | $10.64 | +369.92% | 7 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $40 | $15.02 | +166.31% | 6 | Oct 19, 2022 |
Xeris Biopharma Holdings
Aug 19, 2025
Maintains: Outperform
Price Target: $7 → $9
Current: $7.84
Upside: +14.80%
Akebia Therapeutics
Apr 28, 2025
Initiates: Outperform
Price Target: $7
Current: $3.12
Upside: +124.36%
CorMedix
Mar 7, 2025
Initiates: Outperform
Price Target: $18
Current: $13.70
Upside: +31.39%
Lexicon Pharmaceuticals
Mar 4, 2025
Downgrades: Market Perform
Price Target: $1
Current: $1.09
Upside: -8.26%
Vir Biotechnology
Jan 13, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $5.52
Upside: +262.38%
ARS Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $10.88
Upside: +148.16%
Aquestive Therapeutics
Oct 25, 2024
Maintains: Outperform
Price Target: $12 → $13
Current: $3.95
Upside: +229.53%
Ardelyx
Apr 5, 2024
Initiates: Outperform
Price Target: $14
Current: $6.52
Upside: +114.89%
United Therapeutics
Feb 5, 2024
Initiates: Outperform
Price Target: $330
Current: $391.24
Upside: -15.65%
Cytokinetics
Aug 15, 2023
Initiates: Outperform
Price Target: $58
Current: $49.99
Upside: +16.02%
Apr 11, 2023
Initiates: Market Perform
Price Target: $25
Current: $71.30
Upside: -64.94%
Feb 9, 2023
Reiterates: Market Perform
Price Target: $49
Current: $8.84
Upside: +454.30%
Jan 27, 2023
Maintains: Outperform
Price Target: $12 → $13
Current: $5.51
Upside: +135.93%
Jan 27, 2023
Maintains: Market Perform
Price Target: $8 → $6
Current: $3.46
Upside: +73.66%
Dec 20, 2022
Initiates: Outperform
Price Target: $19
Current: $24.89
Upside: -23.66%
Nov 15, 2022
Maintains: Outperform
Price Target: $110 → $120
Current: $55.15
Upside: +117.59%
Nov 3, 2022
Maintains: Market Perform
Price Target: $75 → $50
Current: $10.64
Upside: +369.92%
Oct 19, 2022
Maintains: Market Perform
Price Target: $60 → $40
Current: $15.02
Upside: +166.31%